PDL BioPharma (US: PDLI)

Last close As at 27/03/2024

2.47

0.00 (0.00%)

Market capitalisation

283m

Edison Investment Research is terminating coverage on PDL BioPharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

PDL BioPharma — Dissolution set for the year end

Healthcare | Update

PDL BioPharma — Selling off Noden

Healthcare | Update

PDL BioPharma — Accelerating asset monetization

Financials

Edison Investment Research is terminating coverage on PDL BioPharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Research

Update

Healthcare

PDL BioPharma — Accelerating asset monetization

Outlook

Healthcare

PDL BioPharma — Returning value to shareholders

Update

Healthcare

PDL BioPharma — Company to seek to monetize assets

Update

Healthcare

PDL BioPharma — Raising guidance

Update

Healthcare

PDL BioPharma — Eyes focused on Evofem

Update

Healthcare

PDL BioPharma — Q119 results

Update

Healthcare

PDL BioPharma — Investing in Evofem

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free